

WHAT IS CLAIMED IS:

1. A pharmaceutical composition for treatment and/or prevention of a disease, a disorder and/or a condition caused by expression of a gene controlled by NF-KB or ets, the composition comprising:
at least one decoy; and
a pharmaceutically acceptable carrier.
2. A composition according to claim 1, wherein the at least one decoy is an NF-KB decoy or a derivative, variant or fragment thereof, and the derivative, variant or fragment thereof has biological activity.
3. A composition according to claim 1, wherein the at least one decoy is an NF-KB decoy.
4. A composition according to claim 1, wherein the at least one decoy is an ets decoy.
5. A composition according to claim 1, wherein the at least one decoy is a chimera decoy of NF-KB and ets.
6. A composition according to claim 1, wherein the disease is cerebral aneurysm, cancer, Marfan's syndrome, aortic detachment, post-angioplasty restenosis, chronic articular rheumatism, asthma , atopic dermatitis, nephritis, renal failure, or plaque rupture.
7. A composition according to claim 1, wherein the pharmaceutically acceptable carrier is a hydrophilic polymer.

8. A composition according to claim 1, wherein the pharmaceutically acceptable carrier is a liposome.

9. A pharmaceutical composition for treatment and/or prevention of a disease, a disorder and/or a condition caused by eosinophilic abnormality, the composition comprising:
at least one decoy; and
a pharmaceutically acceptable carrier.

10. A composition according to claim 9, wherein the at least one decoy is an NF-KB decoy or a derivative, variant or fragment thereof, and the derivative, variant or fragment thereof has biological activity.

11. A composition according to claim 9, wherein the at least one decoy is an NF-KB decoy.

12. A composition according to claim 9, wherein the at least one decoy is an ets decoy.

13. A composition according to claim 9, wherein the at least one decoy are an NF-KB decoy and an ets chimera decoy.

14. A composition according to claim 9, wherein the disease is selected from the group consisting of asthma, allergic diseases, skin diseases, and mycosis.

15. A composition according to claim 9, wherein the disease is selected from the group consisting of bronchial asthma, childhood asthma, allergic asthma , atopic asthma, steroid-resistant asthma (SRA), non-allergic asthma , intrinsic asthma, extrinsic asthma, aspirin-induced asthma, cardiac asthma, and infectious asthma.

16. A composition according to claim 9, wherein the pharmaceutically acceptable carrier is a hydrophilic polymer.

17. A composition according to claim 9, wherein the pharmaceutically acceptable carrier is a liposome.